drugset / Trial / NCT05035069

Efficacy and Safety of Ciprofol Compared to Propofol for Nonintubated General Anesthesia in Patients Undergoing TAVR

NCT05035069

Phase 4 Unknown 24 enrolled Haisco Pharmaceutical Group Co., Ltd.
RandomizedParallel-groupSingle-blindTreatment

Summary

The purpose of this study is to explore the efficacy and safety of ciprofol compared to propofol for non-intubated general anesthesia in patients undergoing transcatheter aortic valve replacement (TAVR).

Timeline

Start
2021-09-03
Primary completion
2022-02-03
Completion
2022-02-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Cipepofol Small molecule 0.2 mg/kg
Subject Cipepofol Small molecule 0.6 mg/kg
Comparator Propofol Small molecule 1 mg/kg
Comparator Propofol Small molecule 3 mg/kg

Indications

No indication recorded.